The concern of generic challenges has consistently loomed above copyright’s blockbuster drug, Viagra, triggering questions about the future of connected pharmaceutical ventures. While initial times saw significant profits, the intellectual property end has allowed the path for less expensive alternatives, possibly lowering profitability and creat